Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ionis Pharmaceuticals has earned $5m license fee from Janssen Biotech for a second orally delivered Generation 2.5 antisense drug.
Subscribe to our email newsletter
IONIS-JBI2-2.5Rx is designed to locally reduce the production of an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease. Jansen will now assume all global development, regulatory, and commercialization responsibilities for IONIS-JBI2-2.5Rx for GI diseases.
"We are pleased that IONIS-JBI2-2.5Rx is advancing into development because we believe this drug has the potential to treat autoimmune disorders in the GI tract that are underserved with current therapies," said Frank Bennett, Ph.D., senior vice president of research at Ionis Pharmaceuticals.
"Our collaboration with Janssen has been very productive. This is the second drug Janssen has licensed in little over a year, which is the direct result of the speed and efficiency of our antisense technology."
Under its global collaboration agreement with Janssen, Ionis is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees.
In addition, Ionis will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized.
IONIS-JBI1-2.5Rx, the first collaboration target, was licensed to Janssen last year and Janssen has assumed all global development, regulatory and commercialization responsibilities related to this drug.